CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure

PartnershipPositive
AI Analysis

Summary

Leo Pharma licensed an oral drug from Tanabe Pharma for genetic light-sensitive skin diseases with up to $435 million in upfront and near-term payments.

Importance:7/10
Sentiment:
0.60
licensing dealrare diseasedermatologyJapanDenmark

Read the original article

Published by Endpoints News on August 18, 2026 7:00 AM

Read Original